Satyen Deka, H Bhattacharjee, H Deka, M J Barman, S M Das (Guwahati, India)

Advantages:

Currently the only treatment option for exudative RD in nanophthalmic eye is surgical (Scleral Resection) with guarded visual prognosis. Intravitreal bevacizumab is a less invasive and safe treatment used for multiple retinal vascular/inflammatory diseases to treat the macular edema, the mode of action of which is through blockage of VEGF mediated reaction. As the basic aim of treatment in nanophthalmic exudative RD is removal of sub retinal fluid, use of intravitreal bevacizumab is rationale which can reduce the macular fluid that has been shown in different studies. Although the effect is transient, repeat injections can be done.

Methods:

After discussing treatment options and obtaining informed consent, two eyes of a 28years old male patient with nonophthalmic exudative RD received off-label intravitreal bevacizumab. Under aseptic precaution 1.25 mg/0.05 ml of the drug was administered using 30-gauge needle through pars plana and followed up next day, at one week and then at one-month interval.

Effectiveness / Safety:

After discussing treatment options and obtaining informed consent, two eyes of a 28years old male patient with nanophthalmic exudative RD received off-label intravitreal bevacizumab. Under aseptic precaution 1.25 mg/0.05 ml of the drug was administered using 30-gauge needle through pars plana and followed up next day, at one week and then at one month interval.

Take home message:

Currently, the treatment option for exudative RD of nanophthalmic eye is only surgical. Scleral resection (window) surgery or sclerotomy to drain the suprachoroidal fluid is the standard technique, and the visual prognosis is guarded. This case report of successful treatment using intravitreal bevacizumab brings the scope of a non-surgical less invasive treatment with a transient effect.